Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Veda N. Giri, Karen E. Knudsen, William K. Kelly, Wassim Abida, Gerald L. Andriole, Chris H. Bangma, Justin E. Bekelman, Mitchell C. Benson, Amie Blanco, Arthur Burnett, William J. Catalona, Kathleen A. Cooney, Matthew Cooperberg, David E. Crawford, Robert B. Den, Adam P. Dicker, Scott Eggener, Neil Fleshner, Matthew L. Freedman, Freddie C. HamdyJean Hoffman-Censits, Mark D. Hurwitz, Colette Hyatt, William B. Isaacs, Christopher J. Kane, Philip Kantoff, R. Jeffrey Karnes, Lawrence I. Karsh, Eric A. Klein, Daniel W. Lin, Kevin R. Loughlin, Grace Lu-Yao, S. Bruce Malkowicz, Mark J. Mann, James R. Mark, Peter A. McCue, Martin M. Miner, Todd Morgan, Judd W. Moul, Ronald E. Myers, Sarah M. Nielsen, Elias Obeid, Christian P. Pavlovich, Stephen C. Peiper, David F. Penson, Daniel Petrylak, Curtis A. Pettaway, Robert Pilarski, Peter A. Pinto, Wendy Poage, Ganesh V. Raj, Timothy R. Rebbeck, Mark E. Robson, Matt T. Rosenberg, Howard Sandler, Oliver Sartor, Edward Schaeffer, Gordon F. Schwartz, Mark S. Shahin, Neal D. Shore, Brian Shuch, Howard R. Soule, Scott A. Tomlins, Edouard J. Trabulsi, Robert Uzzo, Donald J.Vander Griend, Patrick C. Walsh, Carol J. Weil, Richard Wender, Leonard G. Gomella

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods: An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results: Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion: To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

Original languageEnglish
Pages (from-to)414-424
Number of pages11
JournalJournal of Clinical Oncology
Issue number4
StatePublished - Feb 1 2018


Dive into the research topics of 'Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017'. Together they form a unique fingerprint.

Cite this